Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Status:
RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease.
Participants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month "baseline "with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.
Phase:
PHASE4
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Children's Hospital of Philadelphia Emory University National Heart, Lung, and Blood Institute (NHLBI)